Richard Maurice Walmsley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Richard Maurice Walmsley has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Heather Scott
Gentronix Ltd, Alderley Park, United Kingdom
3 shared publicationsNicholas Billinton
Gentronix Ltd., Manchester, UK
2 shared publicationsNick Billinton
Gentronix Ltd, Alderley Park, United Kingdom
2 shared publicationsA.W. Knight
1 shared publication- Adam Rabinowitz
Gentronix Ltd, CTF Building, 46 Grafton Street, Manchester M13 9NT, UK
1 shared publication - Anne Marie Vinggaard
National Food Institute, Technical University of Denmark, 2800 Kongens Lyngby, Denmark
1 shared publication
Latest Publications
- 8 August 2017
- Published by Oxford University Press (OUP) in Mutagenesis
- Vol. 32 (5) , 491-499
The influence of exogenous metabolism on the specificity of in vitro mammalian genotoxicity tests
A two-part study was designed to determine whether the inclusion of the rodent liver ‘S9’ exogenous metabolic activating system contributes to the generation of misleading positive results by the regulator-required in vitro mammalian genotoxicity tests. The mono-oxygenase enzymes in S9 produce direct-acting DNA-reactive electrophiles, and are included in in vitro genotoxicity tests to enhance the detection of substances which only become genotoxic following metabolism. However, as the S9 system lacks ‘detoxifying’ phase 2 factors it was hypothesised that increased chemical metabolism per se may lead to an increase in irrelevant S9 test outcomes in safety assessment. To test this, 89 compounds with positive or negative carcinogenicity data were identified, which produced negative Ames test data (+/– S9), and only produced positive in vitro mammalian test data in the presence of S9. This allowed a determination of whether or not misleading predictions of carcinogenicity by the in vitro mammalian tests were more or less prevalent in the presence of S9. A subset of these compounds was then tested with and without S9 in the GADD45a-GFP genotoxicity test, in order to determine whether misleading in vitro mammalian positive results were generally more prevalent with S9, or reflected particular tests’ liabilities. This study suggests that the use of S9 metabolic activation in in vitro genotoxicity tests does not increase the prevalence of misleading positive results in in vitro mammalian genotoxicity assays, at least amongst Ames negative compounds.
- 8 August 2017
- Published by Oxford University Press (OUP) in Mutagenesis
- Vol. 32 (5) , 491-499
The influence of exogenous metabolism on the specificity of in vitro mammalian genotoxicity tests
A two-part study was designed to determine whether the inclusion of the rodent liver ‘S9’ exogenous metabolic activating system contributes to the generation of misleading positive results by the regulator-required in vitro mammalian genotoxicity tests. The mono-oxygenase enzymes in S9 produce direct-acting DNA-reactive electrophiles, and are included in in vitro genotoxicity tests to enhance the detection of substances which only become genotoxic following metabolism. However, as the S9 system lacks ‘detoxifying’ phase 2 factors it was hypothesised that increased chemical metabolism per se may lead to an increase in irrelevant S9 test outcomes in safety assessment. To test this, 89 compounds with positive or negative carcinogenicity data were identified, which produced negative Ames test data (+/– S9), and only produced positive in vitro mammalian test data in the presence of S9. This allowed a determination of whether or not misleading predictions of carcinogenicity by the in vitro mammalian tests were more or less prevalent in the presence of S9. A subset of these compounds was then tested with and without S9 in the GADD45a-GFP genotoxicity test, in order to determine whether misleading in vitro mammalian positive results were generally more prevalent with S9, or reflected particular tests’ liabilities. This study suggests that the use of S9 metabolic activation in in vitro genotoxicity tests does not increase the prevalence of misleading positive results in in vitro mammalian genotoxicity assays, at least amongst Ames negative compounds.
- 1 October 2015
- Published by Elsevier in Toxicology in Vitro
- Vol. 29 (7) , 1425-1435
The ‘BlueScreen HC’ assay as a decision making test in the genotoxicity assessment of flavour and fragrance materials
- 1 October 2015
- Published by Elsevier in Toxicology in Vitro
- Vol. 29 (7) , 1425-1435
The ‘BlueScreen HC’ assay as a decision making test in the genotoxicity assessment of flavour and fragrance materials
- 1 January 2015
- Published by Elsevier in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
- Vol. 777, 68-72
Ames positive boronic acids are not all eukaryotic genotoxins
- 1 January 2015
- Published by Elsevier in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
- Vol. 777, 68-72
Ames positive boronic acids are not all eukaryotic genotoxins
- Open Access
- 1 January 2013
- Published by Oxford University Press (OUP) in Toxicology Research
- Vol. 2 (5) , 343-351
Applicability domain of the GADD45a reporter assays: non-steroidal anti-inflammatory drugs do not produce misleading genotoxicity results
Increased expression of the GADD45a gene is a very specific biomarker of genotoxin exposure in TK6 cells, and has been exploited in green fluorescent protein and luciferase reporter genotoxicity assays. A recent European Food Safety Authority suggested that the GADD45a-reporter genotoxicity assays might produce misleading positive results for non-steroidal anti-inflammatory drugs. This study was conceived to test the hypothesis that these drugs should be excluded from the applicability domain of the TK6 cell GADD45a GreenScreen HC and BlueScreen HC reporter assays. Data from published screening and validation studies have been reviewed, and new test data have been generated from 20 NSAIDS, from both reporter assays, both in the presence and absence of metabolic activation. The data fail to support this hypothesis: the high specificity of the GADD45a reporter assays is maintained amongst NSAIDs.
- 1 January 2013
- Published by Oxford University Press (OUP) in Toxicology Research
- Vol. 2 (5) , 343-351
Open AccessApplicability domain of the GADD45a reporter assays: non-steroidal anti-inflammatory drugs do not produce misleading genotoxicity results
Increased expression of the GADD45a gene is a very specific biomarker of genotoxin exposure in TK6 cells, and has been exploited in green fluorescent protein and luciferase reporter genotoxicity assays. A recent European Food Safety Authority suggested that the GADD45a-reporter genotoxicity assays might produce misleading positive results for non-steroidal anti-inflammatory drugs. This study was conceived to test the hypothesis that these drugs should be excluded from the applicability domain of the TK6 cell GADD45a GreenScreen HC and BlueScreen HC reporter assays. Data from published screening and validation studies have been reviewed, and new test data have been generated from 20 NSAIDS, from both reporter assays, both in the presence and absence of metabolic activation. The data fail to support this hypothesis: the high specificity of the GADD45a reporter assays is maintained amongst NSAIDs.
- Open Access
- 22 February 2011
- Published by Wiley in British Journal of Pharmacology
- Vol. 162 (6) , 1250-1258
How accurate is in vitro prediction of carcinogenicity?
Positive genetic toxicity data suggest carcinogenic hazard, and this can stop a candidate pharmaceutical reaching the clinic. However, during the last decade, it has become clear that many non‐carcinogens produce misleading positive results in one or other of the regulatory genotoxicity assays. These doubtful conclusions cost a lot of time and money, as they trigger additional testing of apparently genotoxic candidates, both in vitro and in animals, to discover whether the suggested hazard is genuine. This in turn means that clinical trials can be put on hold. This review describes the current approaches to the ‘misleading positive’ problem as well as efforts to reduce the use of animals in genotoxicity assessment. The following issues are then addressed: the application of genotoxicity testing screens earlier in development; the search for new or improved in vitro genotoxicity tests; proposed changes to the International Committee on Harmonisation guidance on genotoxicity testing [S2(R1)]. Together, developments in all these areas offer good prospects of a more rapid and cost‐effective way to understand genetic toxicity concerns.
- 22 February 2011
- Published by Wiley in British Journal of Pharmacology
- Vol. 162 (6) , 1250-1258
Open AccessHow accurate is in vitro prediction of carcinogenicity?
Positive genetic toxicity data suggest carcinogenic hazard, and this can stop a candidate pharmaceutical reaching the clinic. However, during the last decade, it has become clear that many non‐carcinogens produce misleading positive results in one or other of the regulatory genotoxicity assays. These doubtful conclusions cost a lot of time and money, as they trigger additional testing of apparently genotoxic candidates, both in vitro and in animals, to discover whether the suggested hazard is genuine. This in turn means that clinical trials can be put on hold. This review describes the current approaches to the ‘misleading positive’ problem as well as efforts to reduce the use of animals in genotoxicity assessment. The following issues are then addressed: the application of genotoxicity testing screens earlier in development; the search for new or improved in vitro genotoxicity tests; proposed changes to the International Committee on Harmonisation guidance on genotoxicity testing [S2(R1)]. Together, developments in all these areas offer good prospects of a more rapid and cost‐effective way to understand genetic toxicity concerns.
- 19 July 2010
- Published by Elsevier in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
- Vol. 700 (1-2) , 44-50
A pre-validation transferability study of the GreenScreen HC GADD45a-GFP assay with a metabolic activation system (S9)
- 19 July 2010
- Published by Elsevier in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
- Vol. 700 (1-2) , 44-50
A pre-validation transferability study of the GreenScreen HC GADD45a-GFP assay with a metabolic activation system (S9)
- 1 January 2009
- Published by Elsevier in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
- Vol. 672 (1) , 17-19
Genotoxic carcinogen or not genotoxic carcinogen? That is the question
- 1 January 2009
- Published by Elsevier in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
- Vol. 672 (1) , 17-19
Genotoxic carcinogen or not genotoxic carcinogen? That is the question
- 1 June 2008
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 4 (6) , 827-835
GADD45a-GFP GreenScreen HC genotoxicity screening assay
Background: Genetic toxicology is getting very interesting. The International Conference on Harmonisation has drafted new guidance that allows for the registration of pharmaceuticals without the submission of data from in vitro mammalian genotoxicity tests (in vitro micronucleus test, chromosomal aberrations, mouse lymphoma assay). These tests often produce falsely positive predictions of genotoxic carcinogenicity. Objectives: This article reviews the properties of the Gadd45a-GFP (green fluorescent protein) assay, for which positive results appear to provide more reliable predictions of genotoxic carcinogenicity. The criteria for assessment of genotoxicity assays are reviewed. Consideration is given to the value of genotoxicity hazard assessment early in pharmaceutical discovery. Methods: Peer-reviewed data have been reviewed, as well as information contributed to the public domain through conference presentations. Results/conclusion: The Gadd45a assay is increasingly used as a screening tool, and has utility in the prioritisation of Ames-negative compounds prior to in vivo genotoxicity assessment.
- 1 June 2008
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 4 (6) , 827-835
GADD45a-GFP GreenScreen HC genotoxicity screening assay
Background: Genetic toxicology is getting very interesting. The International Conference on Harmonisation has drafted new guidance that allows for the registration of pharmaceuticals without the submission of data from in vitro mammalian genotoxicity tests (in vitro micronucleus test, chromosomal aberrations, mouse lymphoma assay). These tests often produce falsely positive predictions of genotoxic carcinogenicity. Objectives: This article reviews the properties of the Gadd45a-GFP (green fluorescent protein) assay, for which positive results appear to provide more reliable predictions of genotoxic carcinogenicity. The criteria for assessment of genotoxicity assays are reviewed. Consideration is given to the value of genotoxicity hazard assessment early in pharmaceutical discovery. Methods: Peer-reviewed data have been reviewed, as well as information contributed to the public domain through conference presentations. Results/conclusion: The Gadd45a assay is increasingly used as a screening tool, and has utility in the prioritisation of Ames-negative compounds prior to in vivo genotoxicity assessment.
- Open Access
- 28 June 2005
- Published by Oxford University Press (OUP) in Mutagenesis
- Vol. 20 (5) , 317-327
Genetic modification and variations in solvent increase the sensitivity of the yeast RAD54-GFP genotoxicity assay
The yeast (Saccharomyces cerevisiae) RAD54-GFP DNA repair reporter assay (GreenScreen® assay, GSA) can be used for early genotoxicity screening in drug discovery. During the initial validation of this preregulatory assay, a subset of known genotoxic compounds that did not give reproducibly clear positive GSA results was identified. Cell permeability, inherent drug resistance mechanisms, metabolic activation and compound solubility were identified as possible barriers to the detection of specific compounds. In this study three types of modification to the existing assay protocol were explored in order to address these possibilities: (i) modification of the reporter host strain by deletion of genes involved in cell wall integrity or with products functioning as efflux pumps (PDR5, ERG6, SNQ2, YOR1); (ii) expression in the host yeast of human phase I metabolic activation genes and (iii) variation in the test solvent system for compounds with poor aqueous solubility. The modifications described and the assay results presented show how the assay may be tailored to suit specific classes of test compound in a more analytical mode. Improvements in assay sensitivity were seen in the detection of some genotoxins using yeast cell wall mutants and those expressing human cytochrome P450 genes.
- 28 June 2005
- Published by Oxford University Press (OUP) in Mutagenesis
- Vol. 20 (5) , 317-327
Open AccessGenetic modification and variations in solvent increase the sensitivity of the yeast RAD54-GFP genotoxicity assay
The yeast (Saccharomyces cerevisiae) RAD54-GFP DNA repair reporter assay (GreenScreen® assay, GSA) can be used for early genotoxicity screening in drug discovery. During the initial validation of this preregulatory assay, a subset of known genotoxic compounds that did not give reproducibly clear positive GSA results was identified. Cell permeability, inherent drug resistance mechanisms, metabolic activation and compound solubility were identified as possible barriers to the detection of specific compounds. In this study three types of modification to the existing assay protocol were explored in order to address these possibilities: (i) modification of the reporter host strain by deletion of genes involved in cell wall integrity or with products functioning as efflux pumps (PDR5, ERG6, SNQ2, YOR1); (ii) expression in the host yeast of human phase I metabolic activation genes and (iii) variation in the test solvent system for compounds with poor aqueous solubility. The modifications described and the assay results presented show how the assay may be tailored to suit specific classes of test compound in a more analytical mode. Improvements in assay sensitivity were seen in the detection of some genotoxins using yeast cell wall mutants and those expressing human cytochrome P450 genes.